Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer Cells

Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level

(2015) Theodoros Karantanos et al.   EUROPEAN UROLOGY

Steap4 attenuates high glucose and S100B-induced effects in mesangial cells

(2015) Chao-Tang Chuang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Heteronemin, a Spongean Sesterterpene, Induces Cell Apoptosis and Autophagy in Human Renal Carcinoma Cells

(2015) Szu-Ying Wu et al.   Biomed Research International

Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer

(2015) Zhiqiang Han et al.   Oncotarget

Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells

(2014) Sakthivel Muniyan et al.   CANCER LETTERS

Proopiomelanocortin gene delivery induces apoptosis in melanoma through NADPH oxidase 4-mediated ROS generation

(2014) Guei-Sheung Liu et al.   FREE RADICAL BIOLOGY AND MEDICINE

STAT3 inhibitor NSC74859 radiosensitizes esophageal cancer via the downregulation of HIF-1α

(2014) Chi Zhang et al.   TUMOR BIOLOGY

In vitro characterisation of the anti-intravasative properties of the marine product heteronemin

(2013) Sabine Kopf et al.   ARCHIVES OF TOXICOLOGY

Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor

(2013) Sachiyo Nishida et al.   CANCER SCIENCE

Heteronemin, a marine sponge terpenoid, targets TDP-43, a key factor in several neurodegenerative disorders

(2013) Chiara Cassiano et al.   CHEMICAL COMMUNICATIONS

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma

(2013) L. Goyal et al.   CLINICAL CANCER RESEARCH

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

(2013) T Karantanos et al.   ONCOGENE

Castration-resistant prostate cancer: systemic therapy in 2012

(2012) FC Maluf et al.   Clinics

„Transforming growth factor β“ im Prostatakarzinom

(2012) M.B. Stope et al.   UROLOGE

Small Molecule Inhibitors of STAT3 for Cancer Therapy

(2011) M. Zhao et al.   CURRENT MEDICINAL CHEMISTRY

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer

(2011) Geert J. L. H. van Leenders et al.   PLoS One

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression

(2011) C.-I. Hwang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systemic Pro-opiomelanocortin Expression Induces Melanogenic Differentiation and Inhibits Tumor Angiogenesis in Established Mouse Melanoma

(2010) Guei-Sheung Liu et al.   HUMAN GENE THERAPY

Heteronemin, a spongean sesterterpene, inhibits TNFα-induced NF-κB activation through proteasome inhibition and induces apoptotic cell death

(2009) Marc Schumacher et al.   BIOCHEMICAL PHARMACOLOGY

Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy

(2009) M. P. Steinkamp et al.   CANCER RESEARCH

Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock

(2009) Zsolt Bikadi et al.   Journal of Cheminformatics

Stat3 Promotes Metastatic Progression of Prostate Cancer

(2008) Junaid Abdulghani et al.   AMERICAN JOURNAL OF PATHOLOGY

STAT3 as a target for inducing apoptosis in solid and hematological tumors

(2008) Khandaker Al Zaid Siddiquee et al.   CELL RESEARCH

Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells

(2007) Ajay P. Singh et al.   CANCER LETTERS